<DOC>
	<DOCNO>NCT02371980</DOCNO>
	<brief_summary>The purpose study evaluate efficacy vortioxetine ( 5 , 10 , 20 mg ) versus placebo first 28 week 32-week double-blind treatment period prevention relapse participant major depressive disorder ( MDD ) respond acute treatment vortioxetine 10 mg .</brief_summary>
	<brief_title>Vortioxetine , 5 , 10 , 20 mg , Relapse Prevention Study Adults With Major Depressive Disorder</brief_title>
	<detailed_description>The drug test study call vortioxetine . Vortioxetine test prevention relapse adult major depressive disorder ( MDD ) respond daily treatment vortioxetine . This study look relapse rate MDD people take vortioxetine . The study enroll approximately 1100 participant . All participant receive vortioxetine 10 mg open-label first 16 week study . Participants meet appropriate MDD response criterion Week 8 Visit Week 16 Visit eligible randomization double-blind treatment period . Participants randomly assign ( chance , like flip coin ) one four treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Vortioxetine 5 mg - Vortioxetine 10 mg - Vortioxetine 20 mg - Placebo ( dummy inactive pill ) - capsule look like study drug active ingredient All participants ask take one capsule time day throughout study . This multi-center trial conduct United States . The overall time participate study 55 week . Participants make 19 visit clinic , contact telephone 4 week last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Suffers recurrent major depressive disorder ( MDD ) primary diagnosis accord Diagnostic &amp; Statistical Manual Mental Disorders , 4th Edition Text Revision ( DSMIVTR ) criterion ( classification code 296.3x ) , current episode confirm Mini International Neuropsychiatric Interview ( MINI ) . 4 . Reported duration current episode ≥8 week ≤18months . 5 . Had least 2 major depressive episode ( MDEs ) current episode . 6 . Has MontgomeryÅsberg Depression Rating Scale ( MADRS ) total score ≥26 Screening Baseline I visit . 7 . Is man woman age 18 75 year , inclusive . 8 . A female participant childbearing potential sexually active nonsterilized male partner agree routinely use adequate contraception signing inform consent throughout duration study 30 day last dose . 1 . Has receive investigational compound within 30 day prior screen 5 halflives prior screen , whichever longer . 2 . Has previously currently participate study . 3 . Has participate 2 clinical study year prior screening , participate clinical trial psychiatric condition exclusionary per protocol . 4 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 5 . Has one following : 1 . Any current psychiatric disorder primary focus treatment MDD define DSMIVTR , assess MINI . 2 . Current history : manic hypomanic episode , schizophrenia psychotic disorder , include schizoaffective disorder , major depression psychotic feature , bipolar depression psychotic feature , obsessive compulsive disorder ( OCD ) , mental retardation , organic mental disorder , mental disorder due general medical condition define DSMIVTR . 3 . Current diagnosis history alcohol substance abuse dependence ( exclude nicotine caffeine ) define DSMIVTR full sustain remission least 3 month day screen ( Participant must also negative urine drug screen Screening Baseline I . ) 4 . Presence history clinically significant neurological disorder ( include epilepsy ) determine investigator . 5 . Neurodegenerative disorder ( Alzheimer disease , Parkinson disease , multiple sclerosis , Huntington disease , etc ) . 6 . Any Axis II disorder define DSMIVTR might compromise study . 6 . The current depressive symptom participant consider investigator resistant 2 adequate antidepressant treatment least 6 week duration . 7 . Has history lack response previous adequate treatment vortioxetine MDD episode adequate treatment consider know dose vortioxetine approve recommend dose range least 6 week duration . 8 . Has receive electroconvulsive therapy , vagal nerve stimulation , repetitive transcranial magnetic stimulation within 6 month prior Screening . 9 . Has start receive formal cognitive behavioral therapy , systematic psychotherapy within 30 day screen plan initiate therapy study ( supportive therapy , marital therapy bereavement counsel allow ) . 10 . Has significant risk suicide accord investigator 's clinical judgment score ≥5 item 10 ( suicidal thought ) MADRS make suicide attempt previous 6 month . 11 . Is required take exclude medication anticipate participant require treatment least 1 disallow concomitant medication study . 12 . Has clinically significant unstable illness , example hepatic impairment renal insufficiency , cardiovascular , pulmonary , gastrointestinal , endocrine , neurological , rheumatologic , immunologic , hematological , infectious , dermatological disorder metabolic disturbance . Note : For purpose protocol fibromyalgia , obstructive sleep apnea , chronic pain diagnosis , morbid obesity ( BMI &gt; 40 ) consider unstable due potential impact assessment primary endpoint . 13 . Has know history currently increase intraocular pressure risk acute narrowangle glaucoma . 14 . Has 1 laboratory value outside normal range , base blood urine sample take Screening Visit , consider investigator clinically significant ; participant follow value Screening Visit : 1 . A serum creatinine value &gt; 1.5 time upper limit normal ( ULN ) . 2 . A serum total bilirubin value &gt; 1.5 xULN . 3 . A serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value &gt; 2 xULN . 15 . Has glycosylated hemoglobin ( HbA1C ) ≥7 % screen prior diagnosis diabetes and/or treatment diabetes . NOTE : Participants know stable diabetes exclude . 16 . Has thyroid stimulate hormone ( TSH ) value outside normal range Screening Visit deem clinically significant investigator . NOTE : Free T4 check TSH range . If free T4 abnormal participant exclude . 17 . Has clinically significant abnormal vital sign determine investigator . 18 . Has abnormal electrocardiogram ( ECG ) determine central reader confirm clinically significant investigator . 19 . Is positive Hepatitis B surface antigen ( HBsAg ) , antihepatitis C virus ( HCV ) antibody , history human immunodeficiency virus ( HIV ) infection . 20 . Has disease take medication , opinion investigator , could interfere assessment safety , tolerability efficacy . 21 . The participant , opinion investigator , unlikely comply clinical study protocol unsuitable reason . 22 . Has history hypersensitivity allergy vortioxetine . 23 . If female , participant pregnant lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period . 24 . The subject consider treatment resistant , eg , subject respond adequate monotherapy treatment least 6 week ' duration , respond combination augmentation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>